Modern insulin continued strong performance
The three modern insulin drugs in Novo Nordisk’s (NVO) portfolio are NovoRapid, Levemir, and NovoMix. These drugs earned 13.6 billion kroner during 4Q15, whereas for fiscal 2015, the portfolio fetched 50.2 billion kroner, which translates to ~21% growth. Around 59% of modern insulin revenue flows from North America. For detailed modern insulin information, please refer to Novo Nordisk Revenues Still Healthy from Modern Insulin Portfolio.
The graph above presents the revenue of the company’s modern insulin portfolio. NovoRapid and Levemir are major contributors that continue to shine and report healthy revenues regardless of cutthroat competition in the segment. Modern insulin and new generation insulin contribute to total insulin sales of ~82%.
Levemir is a key product in Novo’s modern insulin portfolio
Levemir earned 18.3 billion kroner during 2015. The drug witnessed a yearly growth of 29% and proved to be the biggest sales driver. However, following the launch of Tresiba in Europe, Japan, and Korea, Levemir sales were adversely impacted. The volume growth along with the rising insulin market resulted in sales growth of 19% in North America.
The graph above presents percentage terms sales growth for Levemir around the world.
The graph above portrays geography-wise revenue distribution for Levemir. Levemir holds a market share of 24% in volume terms. Though it faced stiff competition from Sanofi’s (SNY) Toujeo, it continued to record significant growth.
For fiscal 2015, NovoRapid recorded revenues amounting to 20.7 billion kroner, a 19% yearly increase in sales growth.
To diversify the risk of investing directly in Novo Nordisk, investors can look for options such as the PowerShares International Dividend Achievers Portfolio (PID). PID holds 0.49% of its total holdings in Novo Nordisk.